Department of Mental Health and Addictions, Central Tuscany NHS Trust, Florence, Italy.
Psychiatry Unit, Department of Health Sciences, University of Florence, Florence, Italy.
Int J Psychiatry Clin Pract. 2021 Sep;25(3):307-315. doi: 10.1080/13651501.2021.1912358. Epub 2021 May 31.
Switching to long-acting injectable (LAI) antipsychotic maintenance treatment (AMT) represents a valuable strategy for schizophrenia. In a recovery-oriented approach, patient-reported outcomes (PROs) such as perceived disability, subjective well-being, and quality of life cannot be neglected.
Forty clinically stable outpatients with schizophrenia treated with oral second-generation antipsychotics were enrolled at the time of switching to the equivalent dose of LAI. 35 subjects completed this 2-year longitudinal, prospective, open-label, observational study. Patients were assessed at baseline, after 1 year, and after 2 years of LAI-AMT, using psychometric scales (Positive And Negative Syndrome Scale, PANSS; Young Mania Rating Scale, YMRS; Montgomery-Åsberg Depression Rating Scale, MADRS), PROs (Subjective Well-Being under Neuroleptics short form, SWN-K; Short Form-36 health survey, SF-36; 12-item World Health Organisation Disability Assessment Schedule, WHODAS 2.0), and caregiver-reported outcomes (12-item WHODAS 2.0).
No psychotic relapses were observed. Psychopathology measures (PANSS total and subscales - excluding negative symptoms), mood symptoms (YMRS, MADRS), perceived disability (patient- and caregiver-administered WHODAS 2.0), subjective well-being (SWN-K), and quality of life (SF-36) showed a concomitant amelioration after 1 year, without further significant variations.
Switching to LAI-AMT may decrease perceived impairment, and increase subjective well-being and quality of life in clinically stable outpatients with schizophrenia.HighlightsLAI treatment may improve outcomes by reducing psychopathology levels and relapses.In a recovery-oriented approach, patient-reported outcomes cannot be neglected.LAI antipsychotics may optimise the subjective experience of treatment.Switching to LAI therapy may result in a reduction in perceived disability.There is a significant correlation between proxy- and patient-reported disability.
转为长效注射(LAI)抗精神病维持治疗(AMT)是精神分裂症的一种有效策略。在以康复为导向的方法中,不能忽视患者报告的结果(PROs),如感知障碍、主观幸福感和生活质量。
40 名接受口服第二代抗精神病药物治疗且病情稳定的精神分裂症门诊患者在转为等效剂量 LAI 时入组。35 名患者完成了这项为期 2 年的纵向、前瞻性、开放标签、观察性研究。患者在基线、1 年后和 LAI-AMT 2 年后使用心理计量学量表(阳性和阴性综合征量表、PANSS;Young 躁狂评定量表、YMRS;蒙哥马利-Åsberg 抑郁评定量表、MADRS)、PROs(神经安定剂下主观幸福感短表、SWN-K;36 项简明健康调查、SF-36;12 项世界卫生组织残疾评定量表、WHODAS 2.0)和照料者报告的结果(12 项 WHODAS 2.0)进行评估。
未观察到精神病复发。精神病理学测量(PANSS 总分和各分量表-不包括阴性症状)、情绪症状(YMRS、MADRS)、感知障碍(患者和照料者评定的 WHODAS 2.0)、主观幸福感(SWN-K)和生活质量(SF-36)在 1 年后同时改善,没有进一步的显著变化。
转为 LAI-AMT 可能会降低精神分裂症门诊患者的感知障碍,并提高其主观幸福感和生活质量。长效治疗可能通过降低精神病理学水平和复发率来改善结果。在以康复为导向的方法中,不能忽视患者报告的结果。长效抗精神病药物可能会优化治疗的主观体验。转为 LAI 治疗可能会降低感知障碍。代理和患者报告的残疾之间存在显著相关性。